A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
2015; Massachusetts Medical Society; Volume: 376; Issue: 4 Linguagem: Inglês
10.1056/nejmoa1414216
ISSN1533-4406
AutoresJason A. Regules, John H. Beigel, Kristopher Paolino, Jocelyn Voell, Amy R. Castellano, Zonghui Hu, P. Rubio Muñoz, James E. Moon, Richard C. Ruck, Jason W. Bennett, Patrick Twomey, Ramiro L. Gutiérrez, Shon Remich, Holly R. Hack, Meagan L. Wisniewski, Matthew Josleyn, Steven A. Kwilas, Nicole Van Deusen, Olivier Tshiani Mbaya, Yan Zhou, Daphne A. Stanley, Jing Wang, Kirsten S. Smith, Meng Shi, Julie E. Ledgerwood, Barney S. Graham, Nancy J. Sullivan, Linda L. Jagodzinski, Sheila A. Peel, Judie B. Alimonti, Jay W. Hooper, Peter Silvera, Brian K. Martin, Thomas P. Monath, W. Jay Ramsey, Charles J. Link, H. Clifford Lane, Nelson L. Michael, Richard T. Davey, Stephen J. Thomas,
Tópico(s)COVID-19 epidemiological studies
ResumoThe worst Ebola virus disease (EVD) outbreak in history has resulted in more than 28,000 cases and 11,000 deaths. We present the final results of two phase 1 trials of an attenuated, replication-competent, recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate designed to prevent EVD.
Referência(s)